Related Experiment Video
Updated: Aug 6, 2026
08:58
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Plasma glucose concentrations in profound neonatal hypoglycemia
Arie L Alkalay1, Laura Flores-Sarnat, Harvey B Sarnat
1Division of Neonatology, Department of Pediatrics, Ahmanson Pediatric Center, David Geffen School of Medicine, UCLA, Los Angeles, CA 90048, USA, and Division of Neurology, Department of Pediatrics, Alberta Children's Hospital, Calgary, Canada.
Clinical Pediatrics
|August 9, 2006
Summary
Defining profound hypoglycemia in newborns is crucial. Studies show over 95% of infants with neurological issues had plasma glucose below 25 mg/dL, indicating a critical threshold for neonatal hypoglycemia.
Area of Science:
- Neonatology
- Pediatric Neurology
- Endocrinology
Background:
- Neonatal hypoglycemia is a common concern.
- Defining profound hypoglycemia is essential for timely intervention.
- Neurological sequelae can result from severe hypoglycemia.
Purpose of the Study:
- To establish low plasma glucose thresholds for profound neonatal hypoglycemia.
- To analyze the relationship between hypoglycemia severity and neurological outcomes.
Main Methods:
- Systematic literature review of neonatal hypoglycemia research.
- Medline database search for relevant publications.
- Analysis of 89 infants with neurological sequelae linked to hypoglycemia.
Main Results:
- Over 95% of affected infants had plasma glucose < 25 mg/dL.
- Hypoglycemia was detected after 10 hours of age in most cases.
- A 21% incidence of neurological injury was observed in infants with similar hypoglycemia exposure.
Conclusions:
- Plasma glucose levels below 25 mg/dL may indicate profound hypoglycemia.
- Early detection and management are critical to prevent neurological injury.
- Further research is needed to refine diagnostic thresholds and treatment protocols.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
01:27Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
01:20Inborn Errors of Metabolism
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...